Fidelity Investments
ONCT

Fidelity Investments’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Fidelity Investments’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-72
Closed -$547 – 5829
2024
Q2 		$547 Buy
+72
New +$620 ﹤0.01% 4857
2023
Q2 		– Sell
-62
Closed -$970 – 5643
2023
Q1 		$970 Sell
62
-10
-14% -$197 ﹤0.01% 4741
2022
Q4 		$1.43K Sell
72
-50
-41% -$995 ﹤0.01% 4586
2022
Q3 		$2K Sell
122
-247
-67% -$5.3K ﹤0.01% 4610
2022
Q2 		$8K Buy
369
+332
+897% +$7.4K ﹤0.01% 4196
2022
Q1 		$1K Buy
+37
New +$1.35K ﹤0.01% 4876
2021
Q2 		– Hold
0
– – – 5057
2021
Q1 		– Hold
0
– – – 4663
2018
Q3 		– Sell
-6,059
Closed -$13M – 3850
2018
Q2 		$13M Sell
6,059
-440
-7% -$1.12M ﹤0.01% 1865
2018
Q1 		$16.2M Buy
6,499
+6,143
+1,726% +$13.7M ﹤0.01% 1807
2017
Q4 		$634K Buy
+356
New +$515K ﹤0.01% 2496

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Fidelity Investments's ONCT Position: Q3 2024 in Review

Fidelity Investments sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2024, closing a stake of 72 shares — an estimated $547 sold.

Fidelity Investments first reported a position in ONCT in Q4 2017 and held it in 9 quarters. The position peaked at $16.2M in Q1 2018. 23 funds tracked by Wall St. Rank hold ONCT as of Q3 2024.

  • Fidelity Investments reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Fidelity Investments sold 72 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $547.
  • Fidelity Investments first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
  • Fidelity Investments's Oncternal Therapeutics, Inc. Common Stock position peaked at $16.2M in Q1 2018.
  • 23 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Fidelity Investments's 13F filing for Q3 2024, filed 13 Nov 2024.